Search

Displaying results 6341 - 6350 of 8010 in total
  1. Drug

    T611

    go.drugbank.com/drugs/DB06391
    Experimental

    T611 is an investigational oral anti-cytomegalovirus (CMV) drug candidate.

  2. Drug

    Protocatechualdehyde

    go.drugbank.com/drugs/DB11268
    Approved

    Protocatechualdehyde possesses antiproliferative and pro-apoptotic properties against human breast cancer cells and colorectal cancer cells by reducing the expression of pro-oncogenes β-catenin and cyclin

  3. Drug

    Exebacase

    go.drugbank.com/drugs/DB16161
    Investigational

    Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia).

  4. Drug

    Fenpyroximate

    go.drugbank.com/drugs/DB16164
    Investigational

    Fenpyroximate is under investigation in clinical trial NCT02533336 (The Effectiveness of Non-pyrethroid Insecticide-treated Durable Wall Liners as a Method for Malaria Control in Endemic Rural Tanzania

  5. Drug

    BEA-17

    go.drugbank.com/drugs/DB18574
    Experimental

    [L48330] It is under investigation for the treatment of glioblastoma.

  6. Drug

    TRX1

    go.drugbank.com/drugs/DB05863
    Experimental

    TRX1 is being developed for the potential treatment of autoimmune diseases in collaboration with Genentech, Inc. TolerRx is currently conducting a Phase I clinical study of TRX1 in the United Kingdom.

  7. Drug

    Taribavirin

    go.drugbank.com/drugs/DB06408
    Investigational

  8. Drug

    Trimethyldiphenylpropylamine

    go.drugbank.com/drugs/DB13361
    Experimental

    Categories: Drugs for Functional Gastrointestinal Disorders
  9. Drug

    tgAAVCF

    go.drugbank.com/drugs/DB17849
    Investigational

    It is being investigated for the treatment of cystic fibrosis.[A259821, A259826]

  10. Drug

    Temanogrel

    go.drugbank.com/drugs/DB05227
    Investigational

    APD791 is intended to lower the risk of arterial thrombosis by reducing the amplification of platelet aggregation, arterial constriction and intimal hyperplasia mediated by serotonin. … APD791 is an oral anti-thrombotic drug candidate being evaluated in a Phase 1 clinical trial by Arena.